 |
Clinical Consideration
Survanta is the market leader and has a long record of safety, efficacy and reliability. Survanta has been extensively studied with over 20 years of research and numerous published clinical studies. Over 750,000 infants have been treated with Survanta since its approval in 1991. Your hospitals can count on Survanta. With manufacturing facilities in North Chicago, Illinois, Survanta is available where and when you need it.
SURVANTA CAN RAPIDLY AFFECT OXYGENATION AND LUNG COMPLIANCE. During controlled clinical trials, the most commonly reported adverse experiences were associated with the dosing procedure: Transient bradycardia 11.9% of doses; oxygen desaturation 9.8% of doses; ETT reflux, fewer than 1% of doses.
* IMS DDD Lung Surfactant Market Purchases July 1991 through June 2007. On file, Abbott Nutrition Marketing Research.
|
|
